Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research

The GLP-1 receptor agonist exenatide has been approved for adjunctive treatment of type 2 diabetes. Continuous GLP-1 infusion improves endothelial function in vivo; no evidence about a beneficial effect of exenatide on vascular function has been published. The aim of our observational study was to evaluate whether exenatide would improve brachial artery function evaluated by the flow mediated dilation (FMD) technique, compared with glimepiride, in subjects with type 2 diabetes. FMD time course was assessed by ultrasound, after 5 min forearm ischaemia, at baseline and after 16-week treatment. At the end of the study FMD was significantly higher in subjects who assumed exenatide compared with glimepiride (9.1 ± 3.6 vs. 5.6 ± 1.0, p = 0.01). Even if limited by the small number of studied subjects, who were not matched in the two treatment groups, this research study represents the first FMD evidence suggesting that chronic administration of exenatide improves arterial dilation.

[1]  A. Gnasso,et al.  Exenatide improves glycemic variability assessed by continuous glucose monitoring in subjects with type 2 diabetes. , 2011, Diabetes technology & therapeutics.

[2]  G. Derosa,et al.  Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. , 2011, European journal of pharmacology.

[3]  M. Netea,et al.  Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes , 2011, Diabetes Care.

[4]  R. Testa,et al.  The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an “Endothelial Resistance” to Glucagon-Like Peptide 1 in Diabetes , 2011, Diabetes Care.

[5]  Ryan A. Harris,et al.  Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. , 2011, American journal of physiology. Heart and circulatory physiology.

[6]  Å. Sjöholm,et al.  Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor , 2010, Molecular and Cellular Endocrinology.

[7]  P. Reaven,et al.  Improvement of Postprandial Endothelial Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes , 2010, Diabetes Care.

[8]  Blair D. Johnson,et al.  Adjusting Flow-Mediated Dilation for Shear Stress Stimulus Allows Demonstration of Endothelial Dysfunction in a Population with Moderate Cardiovascular Risk , 2009, Journal of Vascular Research.

[9]  A. Gnasso,et al.  Endothelial dysfunction or dysfunctions? Identification of three different FMD responses in males with type 2 diabetes. , 2008, Atherosclerosis.

[10]  D. Thijssen,et al.  Importance of Measuring the Time Course of Flow-Mediated Dilatation in Humans , 2008, Hypertension.

[11]  R. Rizza,et al.  Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. , 2007, American journal of physiology. Endocrinology and metabolism.

[12]  J. Holst.  The physiology of glucagon-like peptide 1. , 2007, Physiological reviews.

[13]  Dennis D. Kim,et al.  Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes , 2006, Diabetes, obesity & metabolism.

[14]  K. Pyke,et al.  The relationship between shear stress and flow‐mediated dilatation: implications for the assessment of endothelial function , 2005, The Journal of physiology.

[15]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. , 2005, Diabetes care.

[16]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.

[17]  M. Mocanu,et al.  Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. , 2005, Diabetes.

[18]  J. Holst,et al.  Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. , 2004, American journal of physiology. Endocrinology and metabolism.

[19]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. , 2004, Diabetes care.

[20]  R. Shannon,et al.  Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion , 2004, Circulation.

[21]  J. Keaney,et al.  The clinical implications of endothelial dysfunction. , 2003, Journal of the American College of Cardiology.

[22]  E. Benjamin,et al.  Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. , 2002, Journal of the American College of Cardiology.

[23]  J. Callés-Escandon,et al.  Diabetes and endothelial dysfunction: a clinical perspective. , 2001, Endocrine reviews.